Development and validation of a stability-indicating reverse phase ultra performance liquid chromatographic method for the estimation of nebivolol impurities in active pharmaceutical ingredients and pharmaceutical formulation

doi:10.3724/SP.J.1123.2015.04043

Abstract

Abstract:

A sensitive, stability-indicating gradient reverse phase ultra performance liquid chromatographic method has been developed for the quantitative estimation of nebivolol impurities in active pharmaceutical ingredient (API) and pharmaceutical formulation. Efficient chromatographic separation was achieved on an Acquity BEH C18 column (100 mm×2.1 mm, 1.7 [WTBZ]μ[WTB4]m) with mobile phase of a gradient mixture. The flow rate of the mobile phase was 0.18 mL/min with column temperature of 30 ℃ and detection wavelength of 281 nm. The relative response factor values of (R^*)-2-(benzylamino)-1-((S^*)-6-fluorochroman-2-yl)ethanol ((R^*S^*) NBV-1), (R)-1-((R)-6-fluorochroman-2-yl)-2-((S)-2-((S)-6-fluoro-chroman-2-yl)-2-hydroxyethylamino)ethanol ((RRSS) NBV-3), 1-(chroman-2-yl)-2-(2-(6-fluorochroman-2-yl)-2-hydroxy ethyl amino)ethanol (monodesfluoro impurity), (S)-1-((R)-6-fluorochroman-2-yl)-2-((R)-2((S)-6-fluoro-chroman-2-yl)-2-hydroxyethylamino)ethanol hydrochloride ((RSRS) NBV-3) and (R^*)-1-((S^*)-6-fluorochroman-2-yl)-2-((S^*)-2-((S^*)-6-fluoro-chroman-2-yl)-2-hydroxyethylamino) ethanol ((R^*S^*S^*S^*) NBV-2) were 0.65, 0.91, 0.68, 0.92 and 0.91 respectively. Nebivolol formulation sample was subjected to the stress conditions of acid, base, oxidative, hydrolytic, thermal, humidity and photolytic degradation. Nebivolol was found to degrade significantly under peroxide stress condition. The degradation products were well resolved from nebivolol and its impurities. The peak purity test results confirmed that the nebivolol peak was homogenous and pure in all stress samples and the mass balance was found to be more than 98%, thus proving the stability-indicating power of the method. The developed method was validated according to International Conference on Hormonization (ICH) guidelines with respect to specificity, linearity, limits of detection and quantification, accuracy, precision and robustness.

Key words: impurities, International Conference on Hormonization (ICH) guidelines, nebivolol, reverse phase ultra performance liquid chromatography, stability-indicating

CLC Number:

O658

Veera Raghava Raju THUMMALA, Mohana Krishna LANKA. Development and validation of a stability-indicating reverse phase ultra performance liquid chromatographic method for the estimation of nebivolol impurities in active pharmaceutical ingredients and pharmaceutical formulation[J]. Chinese Journal of Chromatography, 2015, 33(10): 1051-1058.

References

[1] Budavari S. The Merck Index. 14th ed. Hunterdon County: White House Station, 2006: 1112
[2] Martindale W. Martindale: the Extra Pharmacopoeia. 30th ed. New York: Pharmaceutical Press, 1993: 637
[3] Siebert C D, Hansicke A, Nagel T. Chirality, 2007, 20: 103
[4] Pauwels P J, Gommeren W, Van Lommen G, et al. Mol Pharmacol, 1988, 34: 843
[5] Cockcroft J R, Chowienczyk P J, Brett S E, et al. J Pharmacol Exp Ther, 1995, 274: 1067
[6] Gorog S. Talanta, 1997, 44: 1517
[7] Sanjay B B, Bharati R K, Yogini S J, et al. Eurasian J Anal Chem, 2007, 2: 32
[8] ICH, Q3A (R2), 2006
[9] ICH, Q3B (R2), 2006
[10] Shirkhedkar A A, Bugdane P M, Surana S J. Pharmacol Rev, 2008: 141
[11] Rajeshwari K R, Sankar G G, Rao A L, et al. Asian J Chem, 2005, 17: 1259
[12] Aboul-Enein H Y, Ali I. Pharmazie, 2001, 56: 214
[13] Aboul-Enein H X. Biomed Chromatogr, 2003, 17: 111
[14] Thevis M, Opfermann G, Schanzer W. Biomed Chromatogr, 2001, 15: 393
[15] Ramakrishna N V S. J Pharm Biomed Anal, 2005, 39: 1006
[16] Sheshashena Reddy T, Sita Devi P. JPC-J Planar Chromat, 2007, 20: 149
[17] Patel L J, Suhagia B N, Shah P B. Indian J Pharm Sci, 2007, 69: 594
[18] Deepak S, Anurekha J, Alankar S. Pharm Methods, 2011, 2(1): 9
[19] Chandnani V C, Gupta K R, Chopde C T, et al. Int J ChemTech Res, 2010, 2(1): 69
[20] Khandelwal N, Ranawat M S, Amardeep A, et al. Int J ChemTech Res, 2011, 3(1): 290
[21] Priyanka B P, Chetan B C, Dev A J, et al. Int J ChemTech Res, 2012, 4(3): 1241
[22] Keyur B A, Emanual M P, Falgun A M. J Chromat Separation Techniq, 2012, 3(5): 152
[23] Della G T P, Molly M, Anila J, et al. Int J Pharm Sci Rev Res, 2010, 3(2): 139
[24] Anilkumar S, Bhavesh P, Rakshit P. IJPBS, 2010, 1(4): 339
[25] Chetan M B, Hanumanthachar K J, Jayanthi C. IJRPBS, 2012, 3(4): 1594
[26] Pradeep M, Kamal S, Alka G. Int J Pharm Pharm Sci, 2009, 1(2): 5
[27] Gajbhiye A, Dwivedi N. Curr Trends Tech Sci, 2012, 1(2): 118
[28] Rao A L, Rajeswari K R, Sankar G G. E-J Chem, 2010, 7(2): 445
[29] Tripti S, Rajesh P, Dannana G S, et al. Asian J Pharm Clin Res, 2012, 5: 69
[30] Sirisha N, Haripriya A, Swetha B N, et al. Der Pharmacia Lettre, 2013, 5(2): 78
[31] Siddartha B, Sudheer B I, Uttam P P. IJPRBS, 2014, 3(2): 215
[32] Rajagopalan R. Separ Sci Technol, 2004, 5: 27
[33] ICH, Q2(R1), 2005
[34] ICH, Q1A(R2), 2003
[35] ICH, Q1B, 1996